On 1 April 2019, orphan designation (EU/3/19/2151) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for marzeptacog alfa (activated) (also known as MarzAA) for the treatment of haemophilia B.
The sponsorship was transferred to Regintel Limited, Ireland, in October 2019.
Marzeptacog alfa (activated)
|Disease / condition||
Treatment of haemophilia B
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.